HK1111414A1 - Substituted 2h-1,3-benzoxazin-4(3h)-ones - Google Patents

Substituted 2h-1,3-benzoxazin-4(3h)-ones

Info

Publication number
HK1111414A1
HK1111414A1 HK08102004.2A HK08102004A HK1111414A1 HK 1111414 A1 HK1111414 A1 HK 1111414A1 HK 08102004 A HK08102004 A HK 08102004A HK 1111414 A1 HK1111414 A1 HK 1111414A1
Authority
HK
Hong Kong
Prior art keywords
benzoxazin
ones
substituted
Prior art date
Application number
HK08102004.2A
Other languages
English (en)
Inventor
Robert M Scarborough
Meenakshi S Venkatraman
Xiaoming Zhang
Anjali Pandey
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of HK1111414A1 publication Critical patent/HK1111414A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK08102004.2A 2004-09-29 2008-02-22 Substituted 2h-1,3-benzoxazin-4(3h)-ones HK1111414A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61456404P 2004-09-29 2004-09-29
PCT/US2005/034246 WO2006039212A2 (en) 2004-09-29 2005-09-26 Substituted 2h-1,3-benzoxazin-4(3h)-ones

Publications (1)

Publication Number Publication Date
HK1111414A1 true HK1111414A1 (en) 2008-08-08

Family

ID=36142983

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08102004.2A HK1111414A1 (en) 2004-09-29 2008-02-22 Substituted 2h-1,3-benzoxazin-4(3h)-ones

Country Status (14)

Country Link
US (1) US7205296B2 (ja)
EP (1) EP1812429A4 (ja)
JP (1) JP2008514703A (ja)
KR (1) KR20070064356A (ja)
CN (1) CN101031565B (ja)
AU (1) AU2005292314B2 (ja)
BR (1) BRPI0516181A (ja)
CA (1) CA2581638A1 (ja)
HK (1) HK1111414A1 (ja)
IL (1) IL182180A0 (ja)
MX (1) MX2007003836A (ja)
NZ (1) NZ554211A (ja)
WO (1) WO2006039212A2 (ja)
ZA (1) ZA200702688B (ja)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834023B2 (en) * 2006-09-20 2010-11-16 Portola Pharmaceuticals, Inc. Substituted dihydroquinazolines as platelet ADP receptor inhibitors
US7740693B2 (en) 2007-10-01 2010-06-22 Honeywell International Inc. Organic fluorescent sulfonyl ureido benzoxazinone pigments
BR112014010368A2 (pt) 2011-10-31 2017-04-25 Xenon Pharmaceuticals Inc biaril éter sulfonamidas e seu uso como agentes terapêuticos
RU2014121984A (ru) 2011-10-31 2015-12-10 Ксенон Фармасьютикалз Инк. Бензолсульфонамидные соединения и их применение в качестве терапевтических средств
SG11201408284VA (en) * 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
EP2870138B1 (en) 2012-07-06 2018-08-22 Genentech, Inc. N-substituted benzamides and methods of use thereof
WO2014051654A2 (en) * 2012-09-27 2014-04-03 Portola Pharmaceuticals, Inc. Bicyclic oxa-lactam kinase inhibitors
EP2968280A4 (en) 2013-03-14 2016-08-10 Genentech Inc SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF
MX2015010775A (es) 2013-03-15 2016-04-25 Genentech Inc Benzoxazoles sustituidos y metodos para usarlos.
CN105793238B (zh) 2013-11-27 2019-12-24 基因泰克公司 经取代的苯甲酰胺及其使用方法
EP3166939B1 (en) 2014-07-07 2019-06-05 Genentech, Inc. Therapeutic compounds and methods of use thereof
MX2017001554A (es) 2014-08-04 2017-07-24 Nuevolution As Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas oncologicas y autoinmunitarias.
EP4159717A1 (en) 2014-10-06 2023-04-05 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MA41553B1 (fr) 2015-02-16 2020-04-30 The Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy & Undiv Sulfonylurées, composés apparentés, et leur utilisation
WO2016191312A1 (en) 2015-05-22 2016-12-01 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
KR20180067561A (ko) 2015-09-28 2018-06-20 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
WO2017091592A1 (en) 2015-11-25 2017-06-01 Genentech, Inc. Substituted benzamides useful as sodium channel blockers
EP3854782A1 (en) 2016-03-30 2021-07-28 Genentech, Inc. Substituted benzamides and methods of use thereof
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
HUE056716T2 (hu) 2016-09-30 2022-03-28 Vertex Pharma Cisztás firbrózis transzmembrán konduktancia regulátor modulátora, gyógyszerészeti készítmények, kezelési eljárások, és eljárások a modulátor elõállítására
KR20190078587A (ko) 2016-10-17 2019-07-04 제넨테크, 인크. 치료 화합물 및 그의 사용 방법
MX2019006637A (es) 2016-12-09 2019-08-21 Vertex Pharma Modulador del regulador de conductancia transmembrana de fibrosis quistica composiciones farmaceuticas metodos de tratamiento y proceso para producir el modulador.
JP2020511511A (ja) 2017-03-24 2020-04-16 ジェネンテック， インコーポレイテッド ナトリウムチャネル阻害剤としての４−ピペリジン−ｎ−（ピリミジン−４−イル）クロマン−７−スルホンアミド誘導体
CA3066084A1 (en) 2017-06-08 2018-12-13 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
DK3661925T3 (da) 2017-07-07 2022-02-28 Inflazome Ltd Hidtil ukendte sulfonamidcarboxamidforbindelser
CA3069226A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
CN111051280B (zh) 2017-08-02 2023-12-22 弗特克斯药品有限公司 制备吡咯烷化合物的方法
RU2020110219A (ru) 2017-08-15 2021-09-17 Инфлазоум Лимитед Сульфонилмочевины и сульфонилтиомочевины в качестве ингибиторов nlrp3
EP3668843A1 (en) 2017-08-15 2020-06-24 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
US10807994B2 (en) 2017-10-09 2020-10-20 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US11299493B2 (en) 2017-10-09 2022-04-12 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
KR20200097293A (ko) 2017-12-08 2020-08-18 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
TW202000651A (zh) 2018-02-26 2020-01-01 美商建南德克公司 治療性組成物及其使用方法
US11905252B2 (en) 2018-03-02 2024-02-20 Inflazome Limited Compounds
US10947251B2 (en) 2018-03-30 2021-03-16 Genentech, Inc. Therapeutic compounds and methods of use thereof
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
CN113939296A (zh) 2019-04-09 2022-01-14 诺维逊生物股份有限公司 杂环化合物及其用途
US20220168313A1 (en) * 2019-04-09 2022-06-02 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
US20220162229A1 (en) * 2019-04-09 2022-05-26 Nuvation Bio Inc. Heterocyclic compounds and uses thereof
JP7450980B2 (ja) * 2019-12-10 2024-03-18 シャンハイ ジムン バイオファーマ，インコーポレーテッド 神経保護効果を有する化合物およびその調製方法と用途
EP4076657A1 (en) 2019-12-20 2022-10-26 Nuevolution A/S Compounds active towards nuclear receptors
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
MX2022012259A (es) 2020-03-31 2022-12-08 Nuevolution As Compuestos activos frente a receptores nucleares.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
FR2702477B1 (fr) * 1993-03-08 1995-04-28 Synthelabo Dérivés de benzoxazine, leur préparation et leur application en thérapeutique.
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 ４−フルオロサリチル酸類
SE9702774D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
EP1047699A1 (en) 1998-01-15 2000-11-02 Cor Therapeutics, Inc. Platelet adp receptor inhibitors
JP4588877B2 (ja) * 1998-06-17 2010-12-01 ブリストル−マイヤーズ スクイブ カンパニー Ａｄｐ−受容体抗血小板物質と抗高血圧薬の組合せ投与による脳梗塞の予防
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
US20020025961A1 (en) * 2000-02-04 2002-02-28 Scarborough Robert M. Platelet ADP receptor inhibitors
US6906063B2 (en) * 2000-02-04 2005-06-14 Portola Pharmaceuticals, Inc. Platelet ADP receptor inhibitors
EP1331228B1 (en) * 2000-11-01 2007-03-21 Astellas Pharma Inc. Method of screening antiplatelet
US6861424B2 (en) * 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
AU2003289222A1 (en) * 2002-12-06 2004-06-30 Toray Industries, Inc. Benzomorpholine derivatives
AU2004279809B2 (en) * 2003-10-03 2010-07-15 Portola Pharmaceuticals, Inc. Substituted isoquinolinones
DE602004024093D1 (de) * 2003-10-03 2009-12-24 Portola Pharm Inc 2,4-dioxo-3-chinazolinylarylsulfonylharnstoffe

Also Published As

Publication number Publication date
NZ554211A (en) 2010-10-29
BRPI0516181A (pt) 2008-08-26
CN101031565A (zh) 2007-09-05
WO2006039212A2 (en) 2006-04-13
WO2006039212A3 (en) 2007-01-25
CN101031565B (zh) 2010-09-29
US20060069093A1 (en) 2006-03-30
KR20070064356A (ko) 2007-06-20
EP1812429A4 (en) 2010-07-21
MX2007003836A (es) 2007-08-20
IL182180A0 (en) 2007-07-24
JP2008514703A (ja) 2008-05-08
EP1812429A2 (en) 2007-08-01
US7205296B2 (en) 2007-04-17
ZA200702688B (en) 2008-06-25
AU2005292314B2 (en) 2011-11-03
AU2005292314A1 (en) 2006-04-13
CA2581638A1 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
HK1111414A1 (en) Substituted 2h-1,3-benzoxazin-4(3h)-ones
AP2204A (en) 4-phenylamino-quinazolin-6-yl-amides.
EG24739A (en) Fungicidal compositions.
ATE487727T1 (de) Neue 5-substituierte 7-amino-ä1,3üthiazoloä4,5- düpyrimidin-2(3h)-onderivate
AP2005003403A0 (en) Substituted pyrimidinones.
SI1897558T1 (sl) Trden pripravek 2-heksadeciloksi-6-metil-4h-3,1-benzoksazin-e-on
PL2468732T3 (pl) 1H-Chinazolino-2,4-diony
EP1830858A4 (en) 3,6-BICYCLOLIDE
AP2337A (en) Motilide compounds.
AP2006003791A0 (en) 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
HK1107847A1 (en) Parallax-reducing, luminance-preserving diffuser
PL1644343T3 (pl) Pochodne 5-podstawionego chinazolinonu
HK1063969A2 (en) Reaming aiguille.
EP1723125A4 (en) 1,2,4-benzotriazine-1,4-dioxides
GB0505823D0 (en) Boardmate, boardmate adjustable
EP1799492A4 (en) J-BACKRESTS-adjustment mechanism
IL186226A0 (en) (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines
AU156894S (en) Router
ZA200502637B (en) Integrated thermostat.
PL375427A1 (pl) Wylewka, zwłaszcza hydrantowa
ZA200406832B (en) Surgical retractor assembly.
GB0419897D0 (en) T.w.e.d.s
ZA200401937B (en) Saw.
ZA200502164B (en) Geyser.
GB0405594D0 (en) E.v.o.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20140926